VIRX (Viracta) Cumulative Company Assets

Official company branding of Viracta Therapeutics (VIRX)

The historical price action of Viracta Therapeutics (VIRX) assets, reaching 0.00, illustrates the growth of a company whose US base develops combined protocols for combating viral tumors. The business relies on a unique enzyme activation mechanism for lymphoma therapy, which, coupled with partnerships, ensures a steady inflow of funds. The structure also minimizes risks as it prepares its lead drug for final regulatory trials.

Viracta Therapeutics (VIRX) Aggregate Company Assets: for the period 07/04/2022 - 02/16/2025

Financial and market metric breakdowns for viracta.com (VIRX)

- stock quotes and analyst forecast:
Share Price Viracta Therapeutics, Inc.|VIRX - Analyst Consensus Forecast
- business market valuation indicators:
Market Valuation Viracta Therapeutics, Inc.|VIRX - Enterprise Value
- company book value details:
Book Value per Share Viracta Therapeutics|VIRX - Company Book Value|Capitalization to Book Value Ratio viracta.com|VIRX - Company Total Assets
- debt burden and liquidity indicators:
Total Debt to Equity Ratio Viracta Therapeutics|VIRX - Long-Term Debt to Capital|Current Liabilities to Capital Viracta Therapeutics, Inc.|VIRX - Company Debts|Debt to Net Assets Ratio Viracta Therapeutics, Inc.|VIRX - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Viracta Therapeutics|Quick Liquidity Indicator viracta.com
- earnings and market multiples details:
VIRX - Net Income
Basic company analysis:Viracta (VIRX)
Core merchandise of Viracta Therapeutics

Stable utilization of anti-tumor development centers and capacity upgrades are reflected in the total assets chart, where a reverse calculation via ROA combines liabilities and equity to assess the real scale of the business. The growth of this indicator confirms the expansion of the operational base of Viracta Therapeutics (VIRX), although it is critically important to correlate the inflow of resources with the debt load to determine the asset's sustainability.

Key competitors

Total Business Assets ONC|HALO (Halozyme) - Company Total Assets|Cumulative Company Assets Revolution Medicines Inc (RVMD)|Company Total Assets AAPG|Company Total Assets CG Oncology Therapeutics (CGON)|Aggregate Company Assets UroGen Pharma Ltd. URGN|BCAX: Total Business Assets|Personalis - Company Total Assets|Erasca Inc (ERAS) - Cumulative Company Assets|DCTH: Company Total Assets|Company Assets Y-mAbs Corp (YMAB)|Aggregate Company Assets Aura Biosciences, Inc.|CADL: Aggregate Asset Value|Cumulative Company Assets ARAY (Accuray)|SLS (sellaslifesciences.com) - Aggregate Asset Value|Company Total Assets ACTU (Actuate Therapeutics, Inc)|CTOR - Cumulative Company Assets|HURA: Cumulative Company Assets|TARA - Company Total Assets|Fate Therapeutics (FATE) - Aggregate Company Assets|Aadi Bioscience - Aggregate Asset Value|TCRX (TScan Therapeutics Inc) - Company Total Assets|Company Assets Champions Oncology Corp CSBR|Cumulative Company Assets XBIT (XBiotech Inc.)|Aggregate Company Assets CVM (cel-sci.com)|Company Total Assets OSTX (OS Therapies)|Company Total Asset Base radiopharmtheranostics.com (RADX)|ARTV - Aggregate Company Assets|Aggregate Asset Value ANL (Adlai Nortye Ltd.)|VERU: Company Total Assets|tempesttx.com (TPST) - Company Total Assets|XLO (Xilio Therapeutics Inc) - Company Total Assets|Cumulative Company Assets Enochian BioSciences (RENB)|Cumulative Company Assets MURA (Mural Oncology plc)|Aggregate Business Assets KAPA|Company Total Assets OKUR (OnKure Therapeutics)|Company Total Assets CytoMed Therapeutics Ltd GDTC|CRIS: Cumulative Company Assets|Aggregate Asset Value APLM (Apollomics, Inc.)|THAR (Tharimmune Corp) - Cumulative Company Assets|ADVB: Aggregate Business Assets|GNPX (Genprex, Inc.) - Company Total Assets|CLDI: Aggregate Asset Value|Company Total Assets SBFM|XBIO - Company Assets|Aggregate Company Assets Salarius SLRX|Aggregate Asset Value PPBT|AON - Company Total Assets|BGNE - Company Total Assets|Checkpoint Therapeutics, Inc. (CKPT) - Aggregate Company Assets|Total Asset Value of Company ELEV (elevationoncology.com)|ICAD (iCAD Inc.) - Company Total Assets|Company Assets Ikena IKNA|Cumulative Company Assets NTBL (Notable Labs, Ltd.)|Company Total Assets morphosys.com (MOR)|NAYA Biosciences Inc. - Cumulative Company Assets|Aggregate Business Assets AAPGV (Ascentage Pharma Group International)